CL2021001448A1 - Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420). - Google Patents
Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420).Info
- Publication number
- CL2021001448A1 CL2021001448A1 CL2021001448A CL2021001448A CL2021001448A1 CL 2021001448 A1 CL2021001448 A1 CL 2021001448A1 CL 2021001448 A CL2021001448 A CL 2021001448A CL 2021001448 A CL2021001448 A CL 2021001448A CL 2021001448 A1 CL2021001448 A1 CL 2021001448A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrido
- arteriosclerosis
- rheumatoid arthritis
- isopropylamino
- piperazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Walking Sticks, Umbrellas, And Fans (AREA)
Abstract
Se proporcionan formas cristalinas de un compuesto derivado de pirido[3, 4–d]pirimidina que tiene excelente actividad inhibidora de cdk4/6, que son útiles para la prevención o el tratamiento de artritis reumatoide, arteriosclerosis, fibrosis pulmonar, infarto cerebral y/o cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016229973 | 2016-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001448A1 true CL2021001448A1 (es) | 2022-01-14 |
Family
ID=62196036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001420A CL2019001420A1 (es) | 2016-11-28 | 2019-05-24 | Cristal de derivado de pirido[3,4–d]pirimidina o su solvato. |
| CL2021001447A CL2021001447A1 (es) | 2016-11-28 | 2021-06-02 | Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420). |
| CL2021001448A CL2021001448A1 (es) | 2016-11-28 | 2021-06-02 | Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420). |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001420A CL2019001420A1 (es) | 2016-11-28 | 2019-05-24 | Cristal de derivado de pirido[3,4–d]pirimidina o su solvato. |
| CL2021001447A CL2021001447A1 (es) | 2016-11-28 | 2021-06-02 | Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420). |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11261182B2 (es) |
| EP (1) | EP3546456B1 (es) |
| JP (2) | JP6745905B2 (es) |
| KR (1) | KR102352637B1 (es) |
| CN (1) | CN109996800B (es) |
| AU (1) | AU2017364805B2 (es) |
| CA (1) | CA3041854A1 (es) |
| CL (3) | CL2019001420A1 (es) |
| CO (1) | CO2019005513A2 (es) |
| CY (1) | CY1125045T1 (es) |
| DK (1) | DK3546456T3 (es) |
| EC (1) | ECSP19037197A (es) |
| ES (1) | ES2905437T3 (es) |
| HR (1) | HRP20220065T1 (es) |
| HU (1) | HUE057706T2 (es) |
| IL (1) | IL266313B2 (es) |
| LT (1) | LT3546456T (es) |
| MA (1) | MA45887B1 (es) |
| MX (1) | MX382362B (es) |
| MY (1) | MY199852A (es) |
| PE (2) | PE20191133A1 (es) |
| PH (1) | PH12019500905A1 (es) |
| PL (1) | PL3546456T3 (es) |
| PT (1) | PT3546456T (es) |
| RS (1) | RS63004B1 (es) |
| SI (1) | SI3546456T1 (es) |
| TW (1) | TWI755452B (es) |
| UA (1) | UA124273C2 (es) |
| WO (1) | WO2018097295A1 (es) |
| ZA (1) | ZA201902828B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025070601A1 (ja) * | 2023-09-27 | 2025-04-03 | 帝人ファーマ株式会社 | 関節リウマチ治療薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP46108A (en) | 2002-01-22 | 2011-02-10 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| ATE433967T1 (de) * | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| DE602004017474D1 (de) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| GEP20135785B (en) | 2008-08-22 | 2013-03-11 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| CN105682661B (zh) * | 2013-08-23 | 2020-03-27 | 润新生物公司 | 某些化学实体、组合物和方法 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| DK3150599T3 (en) * | 2014-05-29 | 2019-01-14 | Taiho Pharmaceutical Co Ltd | HIS UNKNOWN TETRAHYDROPYRIDOPYRIMIDE COMPOUND OR SALT THEREOF |
| US9643965B2 (en) | 2014-09-17 | 2017-05-09 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| US10124004B2 (en) * | 2015-05-29 | 2018-11-13 | Teijin Pharma Limited | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
-
2017
- 2017-11-27 PL PL17873876T patent/PL3546456T3/pl unknown
- 2017-11-27 CA CA3041854A patent/CA3041854A1/en active Pending
- 2017-11-27 MY MYPI2019002381A patent/MY199852A/en unknown
- 2017-11-27 HU HUE17873876A patent/HUE057706T2/hu unknown
- 2017-11-27 ES ES17873876T patent/ES2905437T3/es active Active
- 2017-11-27 US US16/463,501 patent/US11261182B2/en active Active
- 2017-11-27 SI SI201731055T patent/SI3546456T1/sl unknown
- 2017-11-27 CN CN201780073120.6A patent/CN109996800B/zh active Active
- 2017-11-27 LT LTEPPCT/JP2017/042437T patent/LT3546456T/lt unknown
- 2017-11-27 EP EP17873876.1A patent/EP3546456B1/en active Active
- 2017-11-27 KR KR1020197015052A patent/KR102352637B1/ko active Active
- 2017-11-27 TW TW106141156A patent/TWI755452B/zh active
- 2017-11-27 HR HRP20220065TT patent/HRP20220065T1/hr unknown
- 2017-11-27 IL IL266313A patent/IL266313B2/en unknown
- 2017-11-27 AU AU2017364805A patent/AU2017364805B2/en active Active
- 2017-11-27 JP JP2018553004A patent/JP6745905B2/ja active Active
- 2017-11-27 PT PT178738761T patent/PT3546456T/pt unknown
- 2017-11-27 MX MX2019005717A patent/MX382362B/es unknown
- 2017-11-27 RS RS20220187A patent/RS63004B1/sr unknown
- 2017-11-27 PE PE2019001068A patent/PE20191133A1/es unknown
- 2017-11-27 WO PCT/JP2017/042437 patent/WO2018097295A1/ja active IP Right Grant
- 2017-11-27 MA MA45887A patent/MA45887B1/fr unknown
- 2017-11-27 UA UAA201905840A patent/UA124273C2/uk unknown
- 2017-11-27 DK DK17873876.1T patent/DK3546456T3/da active
- 2017-11-27 PE PE2023003166A patent/PE20250397A1/es unknown
-
2019
- 2019-04-24 PH PH12019500905A patent/PH12019500905A1/en unknown
- 2019-05-06 ZA ZA2019/02828A patent/ZA201902828B/en unknown
- 2019-05-24 CL CL2019001420A patent/CL2019001420A1/es unknown
- 2019-05-27 CO CONC2019/0005513A patent/CO2019005513A2/es unknown
- 2019-05-27 EC ECSENADI201937197A patent/ECSP19037197A/es unknown
-
2020
- 2020-04-06 JP JP2020068663A patent/JP7149980B2/ja active Active
-
2021
- 2021-06-02 CL CL2021001447A patent/CL2021001447A1/es unknown
- 2021-06-02 CL CL2021001448A patent/CL2021001448A1/es unknown
-
2022
- 2022-03-04 CY CY20221100183T patent/CY1125045T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020015437A2 (es) | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1 | |
| CY1124800T1 (el) | Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου | |
| BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| EA201890827A1 (ru) | Конденсированные производные пиразола в качестве ингибиторов киназы | |
| PH12020550499A1 (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
| ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
| MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
| CO2020000371A2 (es) | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos | |
| ECSP17010481A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| WO2018083635A3 (en) | Tricyclic heterocyclic derivatives and uses thereof | |
| PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
| MX2018009189A (es) | Compuestos de anillo de siete miembros de pirimidina. | |
| CL2019001804A1 (es) | Activador de nrf2. | |
| BR112019008604A2 (pt) | compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2 | |
| ECSP17010482A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| MX374105B (es) | Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas. | |
| WO2016164286A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| BR112021026531A2 (pt) | Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2 | |
| SA519401827B1 (ar) | [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه | |
| BR112019008163A2 (pt) | compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2 |